加科思发布KRAS抑制剂临床数据,单药治疗客观缓解率达47.9%

财中社
07 Jan

财中社1月7日电加科思-B(01167)发布自愿公告,宣布其自主研发的KRAS抑制剂戈来雷塞的注册性临床试验数据已在医学期刊《自然医学》上发表。公告中提到,该公司首次完整公开了戈来雷塞在治疗KRAS G12C突变的二线或以上肺癌患者中的临床数据。关键性二期临床试验显示,单药治疗的客观缓解率为47.9%(56/117),中位无进展生存期为8.2个月,中位总生存期为13.6个月。戈来雷塞表现出良好的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10